Evaluation of the Effectiveness and Safety of Mesenchymal Stem Cell Treatment in Fistulising Crohn's Disease: An International Real‐Life Retrospective Multicentre Cohort Study
Péter Bacsur,Daniel Shaham,Zuzana Serclova,Tamás Resál,Bernadett Farkas,Patrícia Sarlós,Pál Miheller,Nitsan Maharshak,Meir Zemel,Ariella Shitrit,Anita Bálint,Anna Fábián,Renáta Bor,Zsófia Bősze,Emese Ivány,Zoltán Szepes,Klaudia Farkas,Illés Tóth,György Lázár,Katerina Vlkova,Aneta Tremerova,Petra Zuskova,Szabolcs Ábrahám,Tamás Molnár
DOI: https://doi.org/10.1111/apt.18359
IF: 9.524
2024-10-30
Alimentary Pharmacology & Therapeutics
Abstract:In a large, real‐world multicentre study, the effectiveness of mesenchymal stem‐cell treatment was observed in more than three‐quarters of Crohn's disease patients with perianal fistulas with reassuring safety and high patient satisfaction. Background Perianal fistulas of Crohn's disease (CD) create a significant burden on patients' lives. However, the efficacy and safety of adipose‐derived mesenchymal stem cell treatment are contradicting, and real‐world evidence is lacking. Aims To examine the usability of darvadstrocel therapy in managing perianal CD. Methods We enrolled patients with CD and perianal fistulas in this retrospective multicenter study. The primary outcome was perianal clinical remission (defined as all treated fistulas closed) at weeks 26 and 52. Secondary outcomes were clinical response rates (≥ 1 fistulas closed), perianal activity (PDAI), patient satisfaction, and adverse events. Data were recorded at baseline and weeks 12, 26 and 52. Prediction of primary outcomes was performed by logistic regression. Results Overall, among 223 patients (male/female ratio: 0.48), perianal clinical remission was achieved in 78.2% and 62.3% until weeks 26 and 52. Baseline PDAI score (OR 0.75), number of fistulas (OR 0.28) and the number of weeks after preparation for surgery (OR 0.98) were associated with treatment failure. The clinical response rates were 84.8% and 79.8% at weeks 26 and 52. Improvement of subjective perianal symptoms was achieved in 77.8% and 78.4% of patients, respectively. Adverse events occurred in 13.5% of patients; perianal abscesses and proctalgia were the most frequently reported. Conclusion Effectiveness data were higher than in clinical trials. The safety profile was reassuring, and patients' satisfaction was high. Appropriate patient selection, fistula preparation and expertise may help to achieve treatment success.
pharmacology & pharmacy,gastroenterology & hepatology